Atlas Trials

A Clinical Study to Evaluate the Safety and Immunogenicity of the Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster

Clinical trial NCT06381843 · COMPLETED

Trial details

NCT number
NCT06381843
Sponsor
WestVac Biopharma Co., Ltd.
Status
COMPLETED
Phase
Not Applicable
Study type
INTERVENTIONAL
COVID-19SARS-CoV-2 Infection
Start date
2022-08-02
Primary completion
2023-03-29
Enrollment
120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.